BIOMAT Database Logo BIOMAT Database Logo

Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. 2010

L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Department of Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan.

BACKGROUND American Society of Clinical Oncology guidelines recommend the use of growth factor after high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support. This randomized trial aims to demonstrate the noninferiority of pegfilgrastim (PEG) compared with filgrastim (FIL) after HDC. METHODS Eighty patients were assigned to FIL at a daily dose of 5 mug/kg or a single fixed dose of PEG (6 mg) 1 day after PBSC. The primary end point was the duration of neutropenia both in terms of absolute neutrophil count (ANC) <0.5 x 10(9)/l and of days to reach an ANC >0.5 x 10(9)/l. RESULTS The mean duration of neutropenia was 6 and 6.2 days and the mean time to reach an ANC >0.5 x 10(9)/l was 11.5 and 10.8 in the FIL and PEG group, respectively. No differences were observed in the mean time to reach an ANC >1.0 x 10(9)/l (12.2 versus 12.0 days) in the incidence of fever (62% versus 56%) and of documented infections (31% versus 25%). The mean duration of antibiotic therapy was 5.7 and 4.0 days in FIL and PEG group, respectively. CONCLUSIONS PEG is not inferior to FIL in hematological reconstitution and represents an effective alternative after HDC and PBSC.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069585 Filgrastim A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, preparation and collection of blood progenitor cells, and for use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. Filgrastim-sndz,G-CSF Recombinant, Human Methionyl,Granix,Neupogen,R-metHuG-CSF,Recombinant-Methionyl Human Granulocyte Colony-Stimulating Factor,Tbo-Filgrastim,Topneuter,Zarxio,G CSF Recombinant, Human Methionyl,R metHuG CSF,Recombinant Methionyl Human Granulocyte Colony Stimulating Factor,Tbo Filgrastim

Related Publications

L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
June 2005, Bone marrow transplantation,
L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
March 2006, Experimental hematology,
L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Kinetics of peg-filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
September 2007, Bone marrow transplantation,
L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
November 2006, European journal of haematology,
L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
March 2005, Journal of cancer research and clinical oncology,
L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Early versus late administration of pegfilgrastim after high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
March 2012, Journal of cancer research and clinical oncology,
L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
January 2003, Current medical research and opinion,
L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.
May 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
Single-dose pegylated-filgrastim versus daily filgrastim after high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies: delayed platelets recovery?
October 2012, Blood transfusion = Trasfusione del sangue,
L Castagna, and S Bramanti, and A Levis, and M G Michieli, and A Anastasia, and R Mazza, and L Giordano, and B Sarina, and E Todisco, and A I Gregorini, and A Santoro
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in lymphoma without blood product support.
November 2000, Bone marrow transplantation,
Copied contents to your clipboard!